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Tamsulosin hydrochloride (TAM), (–)-(R)-5-[2-[[2-(o-ethoxy phenoxy)ethyl]amino]
propyl]-2-methoxy benzene sulfonamide, monohydrochloride, a selective antagonist of
a1-adrenoreceptor, exhibits selectivity for a1-receptors in human prostate. TAM is used
to reduce urinary obstruction and relieve the symptoms associated with symptomatic
benign prostatic hyperplasia. Chemically, finasteride (FINA), is N-(1,1-dimethylethyl)-
-3-oxo-4-aza-5a-androst-1-ene-17b-carboxamide. It is a specific inhibitor of steroid type-
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Reversed-phase high-performance liquid chromatogra-
phy (RP-HPLC) and thin-layer chromatography (TLC)
methods have been developed and validated for simul-
taneous estimation of tamsulosin hydrochloride and fi-
nasteride in bulk drug and in combined dosage forms. RP-
-HPLC separation was achieved on a Phenomenex C18 co
lumn using methanol/0.02 mol L–1 ammonium acetate buf-
fer/triethylamine (79.9 + 20 + 0.1, V/V/V) (pH 9.2) as mo-
bile phase. TLC separation was achieved on an alumini-
um-backed layer of silica gel 60 F254 using toluene/ me-
thanol/ triethylamine (9 + 1.5 + 1, V/V/V) as eluent.
Quantification was achieved with photodiode array (PDA)
detection at 235 nm over the concentration range 0.5–16
and 1–50 mg mL–1 with mean recovery of 99.8 ± 0.9 and
100.0 ± 0.8 % for tamsulosin hydrochloride and finaste-
ride, respectively, by the RP-HPLC method. Quantifica-
tion was achieved with UV detection at 270 nm over the
concentration range 100–2000 ng per spot and 250–5000
ng per spot with mean recovery of 98.9 ± 0.9 and 99.6 ±
0.7 % for tamsulosin hydrochloride and finasteride, respecti-
vely, by the TLC method. Both methods are simple, pre-
cise, accurate and sensitive and are applicable to the si-
multaneous determination of tamsulosin hydrochloride and
finasteride in bulk drug and in combined dosage forms.
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-II 5a-reductase, an intracellular enzyme that converts the androgen testosterone into
5a-dihydrotestosterone hormone responsible for prostate growth. Combination of both
drugs is indicated for the treatment of symptomatic benign prostatic hyperplasia in men
with an enlarged prostate (1-3).
Literature survey reveals various LC-MS (4-6) and HPLC (7) methods for determi-
nation of TAM in biological fluids and in pharmaceuticals. Recently, a LC-MS-MS me-
thod has been found for simultaneous estimation of tamsulosin hydrochloride and duta-
steride in human plasma (8). A few LC-MS (9-11), HPLC (12, 13) and HPTLC (14) methods
have been previously reported for the determination of FINA in biological fluids and in
pharmaceuticals.
To the author’s best knowledge, no method has been reported for simultaneous es-
timation of TAM and FINA in combined pharmaceutical dosage forms. Hence, it was
thought to be of interest to develop RP-HPLC and TLC methods for simultaneous esti-
mation of TAM and FINA in bulk as well as in combined dosage forms.
EXPERIMENTAL
Apparatus
A Shimadzu (Japan) RP-HPLC instrument (LC-2010HT) equipped with a photodiode
array detector, autosampler with 20-mL loop, Phenomenex C18 column (250 mm ´ 4.6 mm
id, 5 mm particle size) and Class-VP software were used. For TLC, a Linomat V auto-
sprayer, Scanner-III, flat bottom and twin trough developing chambers and viewing cab-
inet with dual wavelength UV lamps (Camag, Switzerland) were used. TLC plates used
were silica gel with a fluorescent indicator at 254 nm, layer thickness 0.2 mm, 10 ´ 10 cm,
aluminium backing (E. Merck, Germany).
Reagents and materials
Tamsulosin hydrochloride and finasteride pure powder were gifts from Intaas Phar-
maceutical Limited, India. Methanol (RP-HPLC grade) and toluene, methanol, ammo-
nium acetate and triethylamine were purchased from s.d. Fine Chem. Ltd, India. Water
for RP-HPLC was prepared by triple glass distillation and filtered through a nylon
0.45-mm membrane filter (Gelman Laboratory, India). Tablets of two different brands
(brand A: Veltam F (0.4 mg TAM + 5 mg FINA), Intaas Pharmaceuticals Ltd, India, and
brand B: Urimax F (0.4 mg TAM + 5 mg FINA), Sun Pharmaceutical Ltd, India) were
purchased from the local pharmacy.
Chromatographic conditions
RP-HPLC method. – A Phenomenex C18 (250 mm ´ 4.6 mm id, 5 mm particle size) col-
umn was used at 27 °C. The mobile phase consisted of methanol/0.02 mol L–1 ammo-
nium acetate buffer/triethylamine (79.9 + 20 + 0.1, V/V/V) (pH 9.2) and was pumped at
a flow rate of 1 mL min–1. The mobile phase was filtered through a nylon 0.45-mm mem-
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brane filter and degassed before use. Elution was monitored at 235 nm and the injection
volume was 20 mL.
TLC method. – Solutions of both analytes were applied to silica gel 60 F254 TLC plates
by means of a Linomat V automatic spotter equipped with a 100-mL syringe. The plate
was developed in a twin trough chamber previously saturated for 30 min with the mo-
bile phase, toluene/methanol/triethylamine (9 + 1.5 + 1, V/V/V) to 8.5 cm. Spots on the
air-dried plate were scanned with a Scanner III at 270 nm using the deuterium source.
Preparation of TAM and FINA solutions
RP-HPLC method. – Accurately weighed pure powder of each TAM and FINA were
dissolved in methanol to obtain a standard solution of both (100 mg mL–1). Further TAM
(20 mg mL–1) and FINA (50 mg mL–1) solutions were prepared with methanol.
TLC method. – Accurately weighed powder of each TAM and FINA were dissolved
in methanol to obtain a standard solution of TAM and FINA of 1000 mg mL–1. From this
solution, working standard solutions of TAM of 100 mg mL–1 and FINA of 250 mg mL–1
were prepared.
Preparation of sample solution
Thirty tablets of each brand were weighed and powdered. A quantity of tablet pow-
der equivalent to 1 mg of TAM and 12.5 mg of FINA was transferred to a 100-mL volu-
metric flask and 80 mL methanol was added. The solution was sonicated for 15 min, and
the final volume was diluted to the mark with methanol and the solution was then fil-
tered through a nylon 0.20-mm membrane filter to get solution of TAM (10 mg mL–1) and
FINA (125 mg mL–1). This solution is used for TLC method. From this solution a ten fold
dilution was obtained with methanol: of TAM (1 mg mL–1) and FINA (12.5 mg mL–1) for
RP-HPLC method.
Validation
Both RP-HPLC and TLC methods were validated as per ICH guidelines (15).
Calibration curve for RP-HPLC method. – Calibration curves were plotted over the
concentration range 0.5–16 mg mL–1 for TAM and 1–50 mg mL–1 for FINA. Accurately
measured aliquots of working standard solutions of TAM and FINA were diluted with
methanol to obtain final concentrations of TAM (0.5, 1, 2, 4, 8, 12 and 16 mg mL–1) and
FINA (1, 5, 10, 20, 30, 40 and 50 mg mL–1). Calibration curves were constructed by plot-
ting peak areas vs. TAM and FINA concentrations, and regression equations were calcu-
lated.
Calibration curve for TLC method. – Calibration curves were plotted over a concentra-
tion range of 100–2000 ng per spot and 250–5000 ng per spot for TAM and FINA, respec-
tively. Standard solution of TAM and FINA (1, 2, 4, 8, 12, 16 and 20 mL) were applied to
the plate. Spots were developed under the chromatographic conditions as described
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above. Calibration curves were constructed by plotting peak areas vs. concentrations
with the help of Win-CATS software.
Accuracy. – The accuracy of the methods was determined by calculating TAM and
FINA recoveries by the standard addition method. Known amounts of standard solu-
tions of TAM (0.50, 1.00 and 1.50 mg mL–1) and FINA (6.25, 12.50 and 18.75 mg mL–1)
were added to prequantified sample solutions of tablet dosage forms for the RP-HPLC
method. TAM (50, 100 and 150 ng per spot) and FINA (625, 1250 and 1875 ng per spot)
were added to prequantified sample solutions of tablet dosage forms for the TLC me-
thod. The amounts of TAM and FINA were estimated by applying these values to the re-
gression equation of the calibration curve.
Instrument precision. – The precision of the instrument was checked by repeatedly
injecting (n = 6) standard solutions of TAM (6 mg mL–1) and FINA (20 mg mL–1) for the
RP-HPLC method and by repeated spotting of the same solution and repeated scanning
of the same spot (n = 6) of TAM (800 ng per spot) and FINA (2000 ng per spot) without
changing the position of plate for the TLC method. Repeatability is reported in terms of
relative standard deviation (RSD).
Method precision. – The intra-day and inter-day precision of the proposed methods
were determined by estimating the corresponding responses 3 times on the same day
and on 3 different days for 3 different concentrations (4, 8 and 12 mg mL–1) of TAM and
FINA (10, 20 and 30 mg mL–1) for the RP-HPLC method, and 800, 1200 and 1600 ng of
TAM per spot and 1000, 2000 and 3000 ng of FINA per spot for the TLC method.
Limit of detection and quantification. – The limit of detection (LOD) of the both drugs
was found by the trial and error method (visual) by injecting progressively low concen-
trations of standard solutions. The lowest concentration of the range at which the analy-




RP-HPLC method. – To optimize the RP-HPLC parameters, several mobile phase com-
positions were assayed. A satisfactory separation and good peak symmetry for TAM
and FINA were obtained with a mobile phase consisting of methanol/0.02 mol L–1 am-
monium acetate buffer/triethylamine (79.9 + 20 + 0.1, V/V/V). Clear baseline was
achieved with photodiode array (PDA) detection at 235 nm (Fig. 1).
TLC method. – Several mobile phases were tested to accomplish good separation of
TAM and FINA. Using the mobile phase toluene/methanol/triethylamine (9 + 1.5 + 1,
V/V/V) and silica gel 60 F254 aluminum-backed plates as a stationary phase, better se-
paration was attained for TAM and FINA with Rf values of 0.36 and 0.65, respectively
(Fig. 3). A wavelength of 270 nm was used for quantification of both drugs.
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Validation of the methods
Linear correlation was obtained between the peak area and concentration of the
drugs. In the RP-HPLC method, linearity range was 0.5–16 mg mL–1 and 1–50 mg mL–1
for TAM and FINA, respectively. In the TLC method, linearity was in the range of
100–2000 ng per spot and 250–5000 ng per spot for TAM and FINA, respectively. Linear-
ity of the calibration curves was validated by the high value of correlation coefficients of
the regression (Table I).
The accuracy of the method was studied by the standard addition method. The
mean recoveries with standard deviation were 99.9 ± 0.9 and 100.0 ± 0.8 for TAM and
FINA, respectively, by RP-HPLC, and 98.9 ± 0.9 and 99.6 ± 0.7 for TAM and FINA, re-
spectively, by the TLC method. The results revealed no interference of excipients during
the analysis by both methods are accurate (Figs. 1b and 2b and Table II).
Both the drugs were well resolved from each other by either HPLC or TLC.
The RSD values of instrument precision for both TAM and FINA were found to be
0.4 % using RP-HPLC and 0.5–0.6 %, using TLC (Table II). The RSD values of inter-day
precision for TAM and FINA by RP-HPLC method were 0.8–1.6 % and intra-day preci-
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Fig. 1. RP-HPLC chromatograms of: a) standard solution with 10 mg mL–1 TAM + 50 mg mL–1 FINA,
b) formulation with 2 mg mL–1 TAM + 25 mg mL–1 FINA, at 235 nm.
Table I. Regression analysis of the calibration curves for TAM and FINA for RP-HPLC and TLC methods
Parameter
RP-HPLC TLC
TAM FINA TAM FINA
Concentration
range
0.5–16 mg mL–1 1–50 mg mL–1 100–2000 ng per spot 250–5000 ng per spot
Slopea 28074 ± 324 82150 ± 23 1.518 ± 0.22 0.743 ± 0.086
Intercepta 7508 ± 77 8714 ± 561 239.34 ± 19.74 143.58 ± 32.91
Coefficient of
determination (R2)
0.9986 0.9981 0.9975 0.9978
a Mean ± SD, n = 5.
sion 0.7–1.0 %. For TLC method inter-day precision RSD values for TAM and FINA were
1.0–1.6 %, and intraday precision were 0.8–1.1 %. Low RSD values indicate that the pro-
posed methods are precise (Table II).
LOD for TAM and FINA was found to be 0.2 and 0.5 mg mL–1 for RP-HPLC and 80
and 200 ng per spot for TLC, respectively. LOQ for TAM and FINA was found to be 0.5
and 1.0 mg mL–1, respectively, for RP-HPLC, and 100 ng per spot and 250 ng per spot re-
spectively for the TLC method. These data show that both methods are sensitive for TAM
and FINA determination (Table II).
System suitability parameters including retention time, theoretical plate number,
tailing factor, asymmetry factor, capacity factor and resolution were investigated and are
listed in Table III.
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Table II. Validation parameters for the proposed RP-HPLC and TLC methods
Parameter
RP-HPLC method TLC method
TAM FINA TAM FINA
LOD 0.2 mg mL–1 0.5 mg mL–1 80 ng per spot 200 ng per spot
LOQ 0.5 mg mL–1 1.0 mg mL–1 100 ng per spot 250 ng per spot
Recovery (accuracy)(%)a 99.9 ± 0.9 100.0 ± 0.8 98.9 ± 0.9 99.6 ± 0.7
Instrument precision
(RSD, %)b
0.4 % 0.4 % 0.5 % 0.6 %
Method precision (RSD, %)b
Intra-day precision
(RSD, %)b
0.5–1.0 % 0.7–0.9 % 0.8–1.0 % 1.0 %
Inter-day precision
(RSD, %)b
0.7–1.1 % 0.9–1.4 % 1.0–1.3 % 1.1–1.6 %
a Mean ± SD, n = 6.
b n = 3.
Table III. System suitability parameters for TAM and FINA for the RP-HPLC method
Parameters TAMa RSD (%) FINAa RSD (%)
Retention time (min) 3.271 0.5 4.735 0.5
Tailing factor 1.195 1.0 1.171 1.0
Asymmetry factor 1.139 1.0 1.268 1.0
Capacity factor 4.289 0.9 6.543 0.7
Number of theoretical plates (N) 2800.66 1.1 4918.52 1.0
Chromatographic resolution (Rs) 2.875 1.3 5.246 0.5
a Mean value, n = 5.
Assay of the tablet dosage form
The proposed methods were applied to determine TAM and FINA in the combined
tablet dosage form (brands A and B). Good compliance (99–101 %) with the label claim
was found for both analytes by both HPLC and TLC (Table IV).
CONCLUSIONS
RP-HPLC and TLC methods were developed for determination of TAM and FINA
in pharmaceutical formulations. Both methods are simple, precise, accurate, specific and
sensitive. Hence, both methods can be extended for routine simultaneous analysis of
TAM and FINA in tablet formulations.
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Fig. 2. TLC densitograms of: a) standard solution with 1600 ng TAM + 400 ng FINA per spot, b) for-
mulation A with 300 ng TAM + 3750 ng FINA per spot at 270 nm.





Mass found (mg) Assay (%)a,b Mass found (mg) Assay (%)a,b
A
TAM 0.40 0.40 98.9 ± 0.6 0.40 99.6 ± 1.2
FINA 5.00 5.03 100.7 ± 1.1 4.99 99.8 ± 1.1
B
TAM 0.40 0.40 99.7 ± 0.8 0.402 100.6 ± 0.8
FINA 5.00 4.97 99.2 ± 1.0 5.00 100.0 ± 1.0
a Percent of the label claim.
b Mean ± SD, n = 5.
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S A @ E T A K
Validirane RP-HPLC i TLC metode za simultano odre|ivanje
tamsulozin hidroklorida i finasterida u istom dozirnom pripravku
DIPTI B. PATEL i NATUBHAI J. PATEL
U radu su opisani razvoj i validacija inverzno fazne kromatografije visoke u~inko-
vitosti (RP-HPLC) i tankoslojne kromatografije (TLC) za simultano odre|ivanje tamsu-
lozin hidroklorida i finasterida kao ~istih supstancija i u kombiniranim tabletama. Za
RP-HPLC odjeljivanje kori{tena je Phenomenex C18 kolona (250 mm, 4,6 mm, 5 mm) i
metanol/0,02 mol L–1 pufer s amonijevim acetatom/trietilamin (79,9+20+0,1, V/V/V)
(pH 9,2) kao pokretna faza, pri protoku 1 mL min–1. TLC odjeljivanje ra|eno je na si-
likagelu 60F254 na aluminijskoj podlozi, koriste}i toluen/metanol/trietilamin (9+1,5+1,
V/V/V) kao eluens. Za detekciju u RP-HPLC metodi kori{tena je fotodioda (PDA) pri
235 nm te je provedena kvantitacija u koncentracijskom podru~ju 0,5–16 mg mL–1 i 1–50
mg mL–1, uz srednji analiti~ki povrat od 99,8 ± 0,9 % za tamsulozin hidroklorid i 100,0 ±
0,8 % za finasterid. Za kvantitaciju u TLC metodi kori{tena je UV detekcija pri 270 nm u
koncentracijskom podru~ju 100–2000 ng po to~ki za tamsulozin hidroklorid i 250–5000
ng po to~ki za finasterid, uz srednji analiti~ki povrat od 98,9 ± 0,9, odnosno 99,6 ± 0,7 %.
Obje metode su jednostavne, precizne, to~ne i osjetljive i mogu se primijeniti za simul-
tano odre|ivanje tamsulozin hidroklorida i finasterida kao ~istih supstancija i u kom-
biniranim dozirnim oblicima.
Klju~ne rije~i: tamsulozin hidroklorid, finasterid, RP-HPLC, TLC
S. K. Patel College of Pharmaceutical Education and Research, Department of Pharmaceutical Chemistry,
Ganpat University, Kherva, Mehsana, Gujarat, India-382711
205
D. B. Patel and N. J. Patel: Validated RP-HPLC and TLC methods for simultaneous estimation of tamsulosin hydrochloride and
finasteride in combined dosage forms, Acta Pharm. 60 (2010) 197–205.
